Press Releases

AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update

Presented positive data from first five patients in Phase 1/2 cystinosis trial 1   showing systemic gene therapy effect at the American Society of Gene and Cell Therapy Annual Meeting; all five patients remain off oral cysteamine Comprehensive Gaucher disease franchise update planned for Q4 2022

Aug 09, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 35,500 restricted stock units (RSUs)

Aug 04, 2022

AVROBIO to Participate in Two Upcoming Investor Conferences in August

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two

Aug 01, 2022

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

AVR-RD-05 is the fourth AVROBIO gene therapy to receive orphan drug designation FDA previously granted rare pediatric disease designation for AVR-RD-05 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 13, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared

Jul 13, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 37,500 restricted stock units (RSUs)

Jul 06, 2022

AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Genetically modified hematopoietic stem cells lead to supraphysiological levels of therapeutic protein in a mouse model of Pompe disease sustained at eight months after administration Substantial reduction in glycogen observed across cardiac and skeletal muscles, as well as CNS Data support plans

May 18, 2022

AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

New early data show key visual motor integration, visual perception and motor coordination measures impacted by cystinosis stabilized or improved post gene therapy Systemic reach of AVR-RD-04 observed across multiple other measures All five dosed patients remain off oral cysteamine post gene

May 17, 2022

AVROBIO to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 16, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C.

May 16, 2022

AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update

Phase 1/2 collaborator-sponsored 1 clinical trial in cystinosis fully enrolled New interim cystinosis clinical data to be presented at the 25 th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) Multiple regulatory interactions planned in 2022 to inform clinical development

May 10, 2022

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to

May 06, 2022



Displaying 1 - 10 of 22

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.